
Results
20
Stocks with a market cap under US$50M.
20 companies
Grace Therapeutics
Market Cap: US$44.4m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$2.12
7D
-2.8%
1Y
-33.9%
Mereo BioPharma Group
Market Cap: US$43.5m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
MREO
US$0.31
7D
-5.2%
1Y
-81.6%
PDS Biotechnology
Market Cap: US$40.8m
A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
PDSB
US$0.26
7D
-64.3%
1Y
-79.1%
Dyadic International
Market Cap: US$36.3m
A biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
DYAI
US$1.05
7D
-2.8%
1Y
23.5%
Bioqual
Market Cap: US$29.1m
Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
BIOQ
US$32.50
7D
0%
1Y
n/a
BioXcel Therapeutics
Market Cap: US$28.7m
Together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
BTAI
US$0.93
7D
8.3%
1Y
-86.3%
Earth Science Tech
Market Cap: US$26.3m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.10
7D
13.8%
1Y
-44.8%
MariMed
Market Cap: US$26.1m
Engages in cultivation, production, and selling of branded cannabis products in the United States.
MRMD
US$0.07
7D
10.2%
1Y
-40.5%
Actinium Pharmaceuticals
Market Cap: US$24.2m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$0.79
7D
-2.1%
1Y
-47.5%
TherapeuticsMD
Market Cap: US$24.0m
Operates as a pharmaceutical royalty company in the United States and internationally.
TXMD
US$2.07
7D
1.5%
1Y
87.3%
MDxHealth
Market Cap: US$23.3m
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
MDXH
US$0.44
7D
-0.2%
1Y
-84.6%
Jasper Therapeutics
Market Cap: US$22.4m
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.
JSPR
US$0.89
7D
34.2%
1Y
-68.7%
Cellectar Biosciences
Market Cap: US$20.8m
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
CLRB
US$2.64
7D
3.1%
1Y
-42.7%
Biofrontera
Market Cap: US$15.5m
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
BFRI
US$1.22
7D
0%
1Y
31.2%
Bio Essence
Market Cap: US$13.5m
Engages in manufacturing and distributing health supplement products.
BIOE
US$0.25
7D
0%
1Y
163.2%
Pharma-Bio Serv
Market Cap: US$9.7m
Operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.
PBSV
US$0.54
7D
27.8%
1Y
-10.0%
Traws Pharma
Market Cap: US$8.2m
A clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer.
TRAW
US$0.54
7D
-2.2%
1Y
-66.8%
CordovaCann
Market Cap: US$4.4m
Engages in the provision of services and investment capital to the processing, production, and retail vertical markets of the cannabis industry in Canada and United States.
LVRL.F
US$0.04
7D
-19.0%
1Y
-32.1%
Ayurcann Holdings
Market Cap: US$58.4k
Provides post-harvest outsourcing solutions to licensed cannabis producers in Canada.
AYUR.F
US$0.0003
7D
0%
1Y
-98.3%
Sunset Island Group
Market Cap: US$34.4k
Through its subsidiary, VBF Brands, grows, cultivates, manufactures, and distributes cannabis in the United States.
SIGO
US$0.0001
7D
0%
1Y
0%